Table 3 Adverse events and serious adverse events
From: Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial
Control (n = 15) | CytoSorb (n = 15) | p value | |
|---|---|---|---|
Total adverse events | 30 | 23 | |
Fatal adverse events | 2 | 1 | |
Patients with fatal adverse event—no. (%) | 2 (13.3) | 1 (6.7) | 1.00 |
Patients with severe non-fatal adverse event—no. (%) | 8 (53.3) | 8 (53.3) | 1.00 |
Patients with at least 1 adverse event—no. (%) | 10 (66.7) | 11 (73.3) | 1.00 |
Adverse events categories | |||
Respiratory—no. (%) | 0 (0) | 2 (13.3) | 0.48 |
Cardiogenic shock—no. (%) | 0 (0) | 1 (6.7) | 1.00 |
Haemorrhagic shock—no. (%) | 0 (0) | 1 (6.7) | 1.00 |
Distributive shock—no. (%) | 2 (13.3) | 1 (6.7) | 1.00 |
Arrhythmias—no. (%) | 8 (53.3) | 5 (33.3) | 0.46 |
Surgical complications—no. (%) | 4 (26.7) | 4 (26.7) | 1.00 |
Infection—no. (%) | 4 (26.7) | 1 (6.7) | 0.33 |
Acute liver failure—no. (%) | 0 (0) | 1 (6.7) | 1.00 |
Acute kidney injury—no. (%) | 4 (26.7) | 4 (26.7) | 1.00 |
Neurological AE (including stroke)—no. (%) | 3 (20.0) | 2 (13.3) | 1.00 |
Electrolyte disorders—no. (%) | 1 (6.7) | 0 (0) | 1.00 |